---
document_datetime: 2025-12-29 13:52:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/deferiprone-lipomed.html
document_name: deferiprone-lipomed.html
version: success
processing_time: 0.1215137
conversion_datetime: 2025-12-31 01:40:11.828201
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Deferiprone Lipomed

[RSS](/en/individual-human-medicine.xml/66762)

##### Authorised

This medicine is authorised for use in the European Union

deferiprone Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Deferiprone Lipomed](#news-on)
- [Related content](#related-content-1419)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Deferiprone Lipomed is an 'iron chelator' (a substance that attaches to iron) that is used to treat iron overload (an excess of iron in the body) in patients with thalassaemia major. This is an inherited disease in which patients are unable to make enough haemoglobin, the protein found in red blood cells that carries oxygen around the body.

Deferiprone Lipomed is used:

- on its own, when standard iron chelator treatment cannot be used or is inadequate;
- in combination with another iron chelator, when treatment with one iron chelator on its own is ineffective or when prevention or treatment of life-threatening conditions requires rapid or intensive correction of iron levels.

Deferiprone Lipomed contains the active substance deferiprone and is a 'generic medicine'. This means that Deferiprone Lipomed contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Ferriprox.

Expand section

Collapse section

## How is Deferiprone Lipomed used?

Deferiprone Lipomed can only be obtained with a prescription and treatment should be started and maintained by a doctor who has experience in the treatment of patients with thalassaemia.

Deferiprone Lipomed is available as 500 mg tablets to be taken by mouth. The usual dose of Deferiprone Lipomed is 75 mg per kilogram body weight each day, divided into three separate doses. Doses above 100 mg/kg a day are not recommended because of a potentially increased risk of side effects. The doctor may adjust the dose of Deferiprone Lipomed depending on the patient's response, which should be measured every two to three months with blood tests. The doctor may interrupt treatment if iron levels in the body get too low.

For more information about using Deferiprone Lipomed, see the package leaflet or contact your doctor or pharmacist.

## How does Deferiprone Lipomed work?

Patients with thalassaemia major need frequent blood transfusions. When patients receive repeated transfusions, the transfused red cells bring iron into the body. However, the body does not have a natural way of removing excess iron, so it builds up. Over time, the excess iron can damage important organs such as the heart or liver. The active substance in Deferiprone Lipomed, deferiprone, is an iron chelator. It attaches to iron in the body to form a compound that can be excreted by the body, mainly in the urine, and to a lesser extent in the stools. This helps to correct the iron overload and prevent damage due to excess iron.

## How has Deferiprone Lipomed been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Ferriprox, and do not need to be repeated for Deferiprone Lipomed.

As for every medicine, the company provided studies on the quality of Deferiprone Lipomed. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Deferiprone Lipomed?

Because Deferiprone Lipomed is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Deferiprone Lipomed authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Deferiprone Lipomed has been shown to have comparable quality and to be bioequivalent to Ferriprox. Therefore, the Agency's view was that, as for Ferriprox, the benefit of Deferiprone Lipomed outweighs the identified risk and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Deferiprone Lipomed?

The company that markets Deferiprone Lipomed will ensure that patients taking the medicine, or their carers, are provided with a reminder card with information on how to take the medicine safely.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Deferiprone Lipomed have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Deferiprone Lipomed are continuously monitored. Side effects reported with Deferiprone Lipomed are carefully evaluated and any necessary action taken to protect patients.

## Other information about Deferiprone Lipomed

Deferiprone Lipomed received a marketing authorisation valid throughout the EU on 20 September 2018.

Deferiprone Lipomed : EPAR - Medicine overview

Reference Number: EMA/553501/2018

English (EN) (100.19 KB - PDF)

**First published:** 05/10/2018

[View](/en/documents/overview/deferiprone-lipomed-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-700)

български (BG) (124.91 KB - PDF)

**First published:**

05/10/2018

[View](/bg/documents/overview/deferiprone-lipomed-epar-medicine-overview_bg.pdf)

español (ES) (100.35 KB - PDF)

**First published:**

05/10/2018

[View](/es/documents/overview/deferiprone-lipomed-epar-medicine-overview_es.pdf)

čeština (CS) (114.68 KB - PDF)

**First published:**

05/10/2018

[View](/cs/documents/overview/deferiprone-lipomed-epar-medicine-overview_cs.pdf)

dansk (DA) (97.83 KB - PDF)

**First published:**

05/10/2018

[View](/da/documents/overview/deferiprone-lipomed-epar-medicine-overview_da.pdf)

Deutsch (DE) (101.17 KB - PDF)

**First published:**

05/10/2018

[View](/de/documents/overview/deferiprone-lipomed-epar-medicine-overview_de.pdf)

eesti keel (ET) (97.74 KB - PDF)

**First published:**

05/10/2018

[View](/et/documents/overview/deferiprone-lipomed-epar-medicine-overview_et.pdf)

ελληνικά (EL) (132.7 KB - PDF)

**First published:**

05/10/2018

[View](/el/documents/overview/deferiprone-lipomed-epar-medicine-overview_el.pdf)

français (FR) (100.12 KB - PDF)

**First published:**

05/10/2018

[View](/fr/documents/overview/deferiprone-lipomed-epar-medicine-overview_fr.pdf)

hrvatski (HR) (117.72 KB - PDF)

**First published:**

05/10/2018

[View](/hr/documents/overview/deferiprone-lipomed-epar-medicine-overview_hr.pdf)

italiano (IT) (99.49 KB - PDF)

**First published:**

05/10/2018

[View](/it/documents/overview/deferiprone-lipomed-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (119.67 KB - PDF)

**First published:**

05/10/2018

[View](/lv/documents/overview/deferiprone-lipomed-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (121.66 KB - PDF)

**First published:**

05/10/2018

[View](/lt/documents/overview/deferiprone-lipomed-epar-medicine-overview_lt.pdf)

magyar (HU) (119.64 KB - PDF)

**First published:**

05/10/2018

[View](/hu/documents/overview/deferiprone-lipomed-epar-medicine-overview_hu.pdf)

Malti (MT) (123 KB - PDF)

**First published:**

05/10/2018

[View](/mt/documents/overview/deferiprone-lipomed-epar-medicine-overview_mt.pdf)

Nederlands (NL) (99.35 KB - PDF)

**First published:**

05/10/2018

[View](/nl/documents/overview/deferiprone-lipomed-epar-medicine-overview_nl.pdf)

polski (PL) (122.9 KB - PDF)

**First published:**

05/10/2018

[View](/pl/documents/overview/deferiprone-lipomed-epar-medicine-overview_pl.pdf)

português (PT) (99.78 KB - PDF)

**First published:**

05/10/2018

[View](/pt/documents/overview/deferiprone-lipomed-epar-medicine-overview_pt.pdf)

română (RO) (127.11 KB - PDF)

**First published:**

05/10/2018

[View](/ro/documents/overview/deferiprone-lipomed-epar-medicine-overview_ro.pdf)

slovenčina (SK) (122.15 KB - PDF)

**First published:**

05/10/2018

[View](/sk/documents/overview/deferiprone-lipomed-epar-medicine-overview_sk.pdf)

slovenščina (SL) (117.6 KB - PDF)

**First published:**

05/10/2018

[View](/sl/documents/overview/deferiprone-lipomed-epar-medicine-overview_sl.pdf)

Suomi (FI) (97.97 KB - PDF)

**First published:**

05/10/2018

[View](/fi/documents/overview/deferiprone-lipomed-epar-medicine-overview_fi.pdf)

svenska (SV) (91.02 KB - PDF)

**First published:**

05/10/2018

[View](/sv/documents/overview/deferiprone-lipomed-epar-medicine-overview_sv.pdf)

Deferiprone Lipomed : EPAR - Risk-management-plan summary

English (EN) (217.23 KB - PDF)

**First published:** 05/10/2018

**Last updated:** 14/07/2023

[View](/en/documents/rmp-summary/deferiprone-lipomed-epar-risk-management-plan-summary_en.pdf)

## Product information

Deferiprone Lipomed : EPAR - Product Information

English (EN) (275.19 KB - PDF)

**First published:** 05/10/2018

**Last updated:** 14/07/2023

[View](/en/documents/product-information/deferiprone-lipomed-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-4)

български (BG) (325.01 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/bg/documents/product-information/deferiprone-lipomed-epar-product-information_bg.pdf)

español (ES) (209 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/es/documents/product-information/deferiprone-lipomed-epar-product-information_es.pdf)

čeština (CS) (152.44 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/cs/documents/product-information/deferiprone-lipomed-epar-product-information_cs.pdf)

dansk (DA) (90.71 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/da/documents/product-information/deferiprone-lipomed-epar-product-information_da.pdf)

Deutsch (DE) (95.47 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/de/documents/product-information/deferiprone-lipomed-epar-product-information_de.pdf)

eesti keel (ET) (88.89 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/et/documents/product-information/deferiprone-lipomed-epar-product-information_et.pdf)

ελληνικά (EL) (297.95 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/el/documents/product-information/deferiprone-lipomed-epar-product-information_el.pdf)

français (FR) (97.46 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/fr/documents/product-information/deferiprone-lipomed-epar-product-information_fr.pdf)

hrvatski (HR) (132.17 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/hr/documents/product-information/deferiprone-lipomed-epar-product-information_hr.pdf)

íslenska (IS) (109.99 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/is/documents/product-information/deferiprone-lipomed-epar-product-information_is.pdf)

italiano (IT) (92.72 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/it/documents/product-information/deferiprone-lipomed-epar-product-information_it.pdf)

latviešu valoda (LV) (188.65 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/lv/documents/product-information/deferiprone-lipomed-epar-product-information_lv.pdf)

lietuvių kalba (LT) (167.46 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/lt/documents/product-information/deferiprone-lipomed-epar-product-information_lt.pdf)

magyar (HU) (291.71 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/hu/documents/product-information/deferiprone-lipomed-epar-product-information_hu.pdf)

Malti (MT) (169.62 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/mt/documents/product-information/deferiprone-lipomed-epar-product-information_mt.pdf)

Nederlands (NL) (193.99 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/nl/documents/product-information/deferiprone-lipomed-epar-product-information_nl.pdf)

norsk (NO) (211.32 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/no/documents/product-information/deferiprone-lipomed-epar-product-information_no.pdf)

polski (PL) (170.97 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/pl/documents/product-information/deferiprone-lipomed-epar-product-information_pl.pdf)

português (PT) (189.41 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/pt/documents/product-information/deferiprone-lipomed-epar-product-information_pt.pdf)

română (RO) (158.2 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/ro/documents/product-information/deferiprone-lipomed-epar-product-information_ro.pdf)

slovenčina (SK) (305.29 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/sk/documents/product-information/deferiprone-lipomed-epar-product-information_sk.pdf)

slovenščina (SL) (130.23 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/sl/documents/product-information/deferiprone-lipomed-epar-product-information_sl.pdf)

Suomi (FI) (91.27 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/fi/documents/product-information/deferiprone-lipomed-epar-product-information_fi.pdf)

svenska (SV) (89.46 KB - PDF)

**First published:**

05/10/2018

**Last updated:**

14/07/2023

[View](/sv/documents/product-information/deferiprone-lipomed-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0011 26/06/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Deferiprone Lipomed : EPAR - All Authorised presentations

English (EN) (12.25 KB - PDF)

**First published:** 05/10/2018

[View](/en/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-710)

български (BG) (41.18 KB - PDF)

**First published:**

05/10/2018

[View](/bg/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_bg.pdf)

español (ES) (21.36 KB - PDF)

**First published:**

05/10/2018

[View](/es/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_es.pdf)

čeština (CS) (27.17 KB - PDF)

**First published:**

05/10/2018

[View](/cs/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (19.29 KB - PDF)

**First published:**

05/10/2018

[View](/da/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (19.53 KB - PDF)

**First published:**

05/10/2018

[View](/de/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (19.42 KB - PDF)

**First published:**

05/10/2018

[View](/et/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (42.2 KB - PDF)

**First published:**

05/10/2018

[View](/el/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_el.pdf)

français (FR) (19.47 KB - PDF)

**First published:**

05/10/2018

[View](/fr/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (25.83 KB - PDF)

**First published:**

05/10/2018

[View](/hr/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (10.59 KB - PDF)

**First published:**

05/10/2018

[View](/is/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_is.pdf)

italiano (IT) (19.43 KB - PDF)

**First published:**

05/10/2018

[View](/it/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (35.79 KB - PDF)

**First published:**

05/10/2018

[View](/lv/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (37.04 KB - PDF)

**First published:**

05/10/2018

[View](/lt/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (32.48 KB - PDF)

**First published:**

05/10/2018

[View](/hu/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (33.09 KB - PDF)

**First published:**

05/10/2018

[View](/mt/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (19.51 KB - PDF)

**First published:**

05/10/2018

[View](/nl/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (10.63 KB - PDF)

**First published:**

05/10/2018

[View](/no/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_no.pdf)

polski (PL) (27.5 KB - PDF)

**First published:**

05/10/2018

[View](/pl/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_pl.pdf)

português (PT) (19.46 KB - PDF)

**First published:**

05/10/2018

[View](/pt/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_pt.pdf)

română (RO) (34.41 KB - PDF)

**First published:**

05/10/2018

[View](/ro/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (26.26 KB - PDF)

**First published:**

05/10/2018

[View](/sk/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.8 KB - PDF)

**First published:**

05/10/2018

[View](/sl/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (19.29 KB - PDF)

**First published:**

05/10/2018

[View](/fi/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (19.24 KB - PDF)

**First published:**

05/10/2018

[View](/sv/documents/all-authorised-presentations/deferiprone-lipomed-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Deferiprone Lipomed Active substance Deferiprone International non-proprietary name (INN) or common name deferiprone Therapeutic area (MeSH)

- Iron Overload
- beta-Thalassemia

Anatomical therapeutic chemical (ATC) code V03AC02

### Pharmacotherapeutic group

All other therapeutic products

### Therapeutic indication

Deferiprone Lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.

Deferiprone Lipomed in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction.

## Authorisation details

EMA product number EMEA/H/C/004710

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Lipomed GmbH

Hegenheimer Strasse 2

Opinion adopted 26/07/2018 Marketing authorisation issued 19/09/2018 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Deferiprone Lipomed : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (149.13 KB - PDF)

**First published:** 26/11/2019

**Last updated:** 14/07/2023

[View](/en/documents/procedural-steps-after/deferiprone-lipomed-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Deferiprone Lipomed : EPAR - Public assessment report

Reference Number: EMA/535221/2018

English (EN) (554.68 KB - PDF)

**First published:** 05/10/2018

[View](/en/documents/assessment-report/deferiprone-lipomed-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Deferiprone Lipomed

Adopted

Reference Number: EMA/CHMP/432508/2018

English (EN) (69.11 KB - PDF)

**First published:** 25/07/2018

**Last updated:** 25/07/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-deferiprone-lipomed_en.pdf)

#### News on Deferiprone Lipomed

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-july-2018) 27/07/2018

#### Related content

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-573)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 14/07/2022

## Share this page

[Back to top](#main-content)